摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-甲基-2-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯 | 887234-98-2

中文名称
3-甲基-2-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯
中文别名
——
英文名称
methyl 3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
英文别名
Methyl 3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-YL)benzoate
3-甲基-2-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲酸甲酯化学式
CAS
887234-98-2
化学式
C15H21BO4
mdl
——
分子量
276.14
InChiKey
ZXMYLQQEDRRWOU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    385.4±35.0 °C(Predicted)
  • 密度:
    1.07±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.08
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    44.8
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
  • 危险性描述:
    H302,H312,H332

SDS

SDS:ccac245f2e76b08641176839b5fc6445
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS
    申请人:COATE Heather R.
    公开号:US20160046640A1
    公开(公告)日:2016-02-18
    The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or indazolyi; R 1 is H, alky], aikoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazofyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, piperazinyl, pyrazolyl, oxadiazolvl, pyrrolidinyl, thiophenyi, morpholinyl, or dialkyiamino; R 2 is H, alkyl, aikoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R 5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, qumazolinyi, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, aikoxy, or halo; and n is 0 or 1, Methods of making the compounds of Formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.
    本发明涉及式I的化合物:其中环A为苯基、萘基、吡啶基、喹啉基、异喹啉基、咪唑吡啉基、呋喃基、噻唑基、异噁唑基、吡唑基、咪唑噻唑基、苯并咪唑基或吲哚基;R1为H、烷基、烷氧基、羟基烷基、OH、卤素、苯基、三唑基、噁唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、哌嗪基、吡唑基、噁二唑基、吡咯烷基、噻吩基、吗啉基或二烷氨基;R2为H、烷基、烷氧基、羟基烷基或卤素;Z为NH、N-烷基或O;R5为吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、喹唑啉基、喹喹啉基、吡唑基、苯并噁唑基、咪唑吡嗪基、三唑咪唑基,可选地取代一个或两个独立选择自烷基、烷氧基或卤素的基团;n为0或1,还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的药物组合物。本发明还涉及使用该化合物的方法。
  • An Asymmetric Aerobic Aza-Wacker-Type Cyclization: Synthesis of Isoindolinones Bearing Tetrasubstituted Carbon Stereocenters
    作者:Guoqiang Yang、Chaoren Shen、Wanbin Zhang
    DOI:10.1002/anie.201203693
    日期:2012.9.3
    It's all in the solvent: An enantioselective variant of an aza‐Wacker‐type cyclization that gives isoindolinones containing tetrasubstituted carbon centers α to the nitrogen atom has been developed (see scheme; tfa=trifluoroacetate). The use of a highly coordinating solvent is crucial for the activity of the catalyst and the stereoselectivity the reaction (up to 99 % ee).
    一切都在溶剂中:已经开发出aza-Wacker型环化的对映体选择性变体,该变体可将含四取代碳中心α的异吲哚啉酮带至氮原子(参见方案; tfa =三氟乙酸盐)。使用高度配位的溶剂对于催化剂的活性和反应的立体选择性(至多99%ee)至关重要 。
  • [EN] SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS<br/>[FR] INHIBITEURS DE LA RÉNINE
    申请人:MERCK FROSST CANADA LTD
    公开号:WO2011057382A1
    公开(公告)日:2011-05-19
    Renin inhibitors which are spirocyclic piperidine derivatives, of formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein: n, for each instance in which it occurs, is independently 0, 1, or 2; W is a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring, A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a first five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to a second five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is -(C=O)-, -CH2- or =CH-; U is a bond or -CH2-, or, when V iS =CH-, U is-CH=; X is =CH-, =CF-, =C(OR3)-, or -(C=O)-; and Y is =CH-, =CF-, =N-, or, for the case when X is -(C=O)-, Y is -N(R3)-.
    肾素抑制剂是螺环哌啶衍生物,其化学式为(I),以及在心血管疾病和肾功能不全治疗中有用的药物组合物。或其立体异构体,或其药用盐,或其药用盐的立体异构体,其中:n,在每次出现时,独立地为0、1或2;W是一个五元或六元饱和或不饱和的杂环或碳环单环,A是(i)一个五元或六元饱和或不饱和的杂环或碳环单环或(ii)一个第一五元或六元饱和或不饱和的杂环或碳环单环,它与第二个五元或六元饱和或不饱和的杂环或碳环单环融合,V是-(C=O)-、-CH2-或=CH-;U是一个键或-CH2-,或者,当V是=CH-时,U是-CH=;X是=CH-、=CF-、=C(OR3)-或-(C=O)-;Y是=CH-、=CF-、=N-,或者,当X为-(C=O)-时,Y是-N(R3)-。
  • Atroposelective Kinetic Resolution of 8<i>H</i>-Indeno[1,2-<i>c</i>]thiophen-8-ols via Pd-Catalyzed C–C Bond Cleavage Reaction
    作者:Junwei Xi、Han Yang、Lin Li、Xue Zhang、Chunyu Li、Zhenhua Gu
    DOI:10.1021/acs.orglett.2c00642
    日期:2022.4.1
    The present work demonstrates a palladium-catalyzed kinetic resolution/ring-opening reaction of 8H-indeno[1,2-c]thiophen-8-ols. The reaction proceeds in a highly regioselective manner, and both optically active thiophene-phenyl atropisomers and stereogenic 8H-indeno[1,2-c]thiophen-8-ols were obtained with high enantiomeric excesses. The synthetic applications of the obtained thiophenyl atropisomers
    本工作展示了钯催化的 8 H-茚并[1,2 - c ]噻吩-8-醇的动力学拆分/开环反应。该反应以高度区域选择性的方式进行,并且以高对映体过量获得了光学活性噻吩-苯基阻转异构体和立体异构 8 H-茚并[1,2 - c ]噻吩-8-醇。简要研究了所得噻吩阻转异构体的合成应用。
  • SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS
    申请人:Chen Austin
    公开号:US20120202837A1
    公开(公告)日:2012-08-09
    Renin inhibitors which are spirocyclic piperidine derivatives, of formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein: n, for each instance in which it occurs, is independently 0, 1, or 2; W is a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring, A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a first five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to a second five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is —(C═O)—, —CH 2 — or ═CH—; U is a bond or —CH2-, or, when V iS ═CH—, U is —CH═; X is ═CH—, ═CF—, ═C(OR 3 )—, or —(C═O)—; and Y is ═CH—, ═CF—, ═N—, or, for the case when X is —(C═O)—, Y is —N(R 3 )—.
    Renin抑制剂是一种螺环哌啶衍生物,其化学式为(I),以及其在心血管疾病和肾功能不全治疗中有用的制药组合物,或其立体异构体,或其药学上可接受的盐,或其立体异构体的药学上可接受的盐,其中:n,在每个出现的情况下,独立地为0、1或2;W为五元或六元饱和或不饱和杂环或碳环单环,A为(i)五元或六元饱和或不饱和杂环或碳环单环,或(ii)第一个与第二个五元或六元饱和或不饱和杂环或碳环单环融合的五元或六元饱和或不饱和杂环或碳环单环,V为—(C═O)—、—CH2—或═CH—;U为键或—CH2-,或当V为═CH—时,U为—CH═;X为═CH—、═CF—、═C(OR3)—或—(C═O)—;Y为═CH—、═CF—、═N—,或当X为—(C═O)—时,Y为—N(R3)—。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐